Theranostics,
the combination of therapeutics and diagnostics,
has emerged as a sophisticated, integrated, and advanced tool in the
prevention and treatment of serious diseases, such as Alzheimer’s
disease (AD). However, the preclinical research of an AD theranostic
molecule is in its infancy and needs to be explored in depth. Herein,
a multifunctional theranostic agent is designed and fabricated by
conjugating an Aβ-specific near-infrared (NIR) fluorescence
probe (F) and by coupling a BBB penetrable peptide (Penetratin,
Pen) onto the basified human serum albumin (HSA-B) that has been recently
proven as an effective amyloid-β (Aβ) inhibitor. Such
an elaborately constructed HSA-B-based molecule (HSA-BFP) possesses
high potency on inhibiting Aβ fibrillogenesis, for example,
increasing SH-SY5Y cell viability from 66.5 to 93%. In addition,
HSA-BFP exhibits favorable stability in the “off–on”
NIR imaging of Aβ plaques and achieves a 2-fold increase of
BBB permeability after the Pen modification. More importantly, in vivo assays with the AD model C. elegans CL2006 indicate that HSA-BFP can specifically image Aβ deposits,
decrease amyloid accumulation, and attenuate Aβ-triggered paralysis.
Thus, HSA-B has been proven as a potent and versatile platform for
the development of AD theranostic agents.